Case Overview

| | |

|---|---|

| Case Type | Class Action Lawsuit |

| Defendants | CVS Health Corp., CaremarkPCS Health LLC |

| Allegations | Kickbacks in exchange for drug formulary access |

| Status | Recently Filed |

| Who May Be Affected | Health plan members who paid for prescription drugs covered under CVS/Caremark formularies |

CVS Health, Caremark Accused of Accepting Kickbacks to Shape Drug Formularies in New Class Action

A newly filed class action lawsuit alleges that CVS Health Corp. and its pharmacy benefit management arm, CaremarkPCS Health LLC, accepted payments from drug manufacturers in exchange for preferential placement on their drug formularies — a practice the lawsuit claims drove up prescription costs for patients.

According to a recent report on the class action filing, the complaint targets the relationship between one of the country's largest pharmacy benefit managers (PBMs) and the pharmaceutical companies whose drugs appear on its approved drug lists.

What Is the Lawsuit About?

At the center of this case is the role that CVS's PBM subsidiary, CaremarkPCS Health, plays in determining which drugs are covered by health insurance plans. PBMs like Caremark act as intermediaries between health insurers, pharmacies, and drug manufacturers — and they wield significant influence over which medications patients can access and at what cost.

The lawsuit alleges that rather than building formularies based solely on clinical value and cost-effectiveness for patients and plan members, CVS and Caremark sold that access to the highest bidder. The complaint claims drug manufacturers made payments — characterized by the lawsuit as kickbacks — in exchange for their products receiving favorable formulary placement, which can mean lower out-of-pocket costs for patients taking those specific drugs and, critically, higher overall costs built into the system for everyone else.

The lawsuit alleges this arrangement harmed health plan members who were steered toward certain medications not because of their medical merit, but because manufacturers had paid for the privilege of being preferred.

Key Allegations at a Glance

The complaint reportedly alleges:

• CVS and Caremark accepted payments from drug manufacturers in exchange for formulary access and preferred drug placement
• These payments functioned as kickbacks, allegedly violating consumer protection and potentially other applicable laws
• Health plan members were financially harmed as a result of drug costs shaped by commercial arrangements rather than clinical or economic standards
• The alleged scheme affected a broad class of consumers who paid for prescription drugs under plans administered by Caremark

Why This Case Matters

The lawsuit arrives amid intense national scrutiny of pharmacy benefit managers and their role in U.S. drug pricing. PBMs have drawn criticism from lawmakers on both sides of the aisle, as well as from the Federal Trade Commission, which released a critical interim report on PBM practices in 2024 concluding that the largest PBMs — including Caremark — may have used their market power in ways that raised costs for patients and plan sponsors.

The CVS/Caremark case fits within a growing wave of litigation and regulatory action targeting what critics describe as conflicts of interest embedded in the PBM business model. When formulary decisions are influenced by manufacturer payments rather than patient outcomes, the lawsuit argues, it is consumers who ultimately pay the price.

Who May Be Affected?

According to the complaint, the proposed class includes individuals who were enrolled in health plans administered or influenced by CaremarkPCS Health and who paid for prescription drugs covered under those formularies. The exact class definition and eligibility criteria will be subject to court proceedings.

If you believe you were enrolled in a health plan managed by CVS Caremark and paid out-of-pocket costs for prescription medications, you may want to monitor developments in this case. Consulting with a qualified attorney is the appropriate next step for anyone seeking to understand whether they may have a role in the litigation.

Key Takeaways

• This is a newly filed lawsuit — no settlement has been reached, and no class has been certified by a court
• PBM litigation is a rapidly evolving area of law, with regulatory and legal pressure building at both the federal and state levels
• Formulary-related kickback allegations are not new to the industry, but cases of this nature are becoming more common as scrutiny of PBM practices grows
• Eligibility for any future class will be determined by the courts — no determination of who qualifies has been made at this stage
• Proof of plan enrollment or prescription purchases may ultimately be relevant if the case advances to a settlement or trial stage; retaining any relevant records is generally advisable

This article is for informational purposes only and does not constitute legal or medical advice. Consult a qualified attorney if you have questions about your legal rights. Consult your doctor before making any changes to your medication.